cannabis was significantly more abused (p=0.0014). Two- The aim of this study was to determine the factors, if any, among patients with schizophrenia that may be associated with relapses.
The specific objectives were to compare the demographic and clinical characteristics of a group of patients with schizophrenia who relapsed, with those who did not relapse.
Method Study sample
The researchers approached the psychiatric nursing staff of mental health outpatient clinics in Johannesburg for a list of possible patients with a diagnosis of schizophrenia. Patients from this list were then randomly selected using the card-shuffling technique.
Patients were included in the study if a review of their records confirmed a diagnosis of schizophrenia according to DSM compared with patients who had not relapsed (Fig. 2) .
Multiple logistic regression models were applied to identify factors that best predicted whether or not a patient could relapse. 
Discussion

Relapse rates
The most common outcome of schizophrenia is usually a remitting course with one or multiple relapses in 50 -92% of cases. and a 2-year rate of >80%. 28 The patients in this study showed similar high rates of relapse. About two-thirds of the patients had at least 1 relapse, with the majority having ≥2 relapses.
In the management of schizophrenia, psychosocial approaches in addition to antipsychotic drug therapy may result in a significant reduction of relapses compared with using antipsychotic treatment only. 28 The psychosocial approaches include community programmes (case management, assertive community treatment, foster home care, day treatment centres and psychosocial rehabilitation centres) and individual or family psychotherapeutic approaches (social skills training, personal therapy and psychoeducation 
Factors associated with relapses Partial adherence
In mentally ill patients, partial adherence to treatment remains a therapeutic challenge and a factor that is difficult to quantify; it is compounded by the fact that adherence rates vary for different psychotropic medications: 58% for antipsychotics and 65% for antidepressants. 31 We observed an overall adherence rate of 64.2%, which concurs with other reported adherence rates. [32] [33] [34] [35] However, this finding must be qualified in that self-reports of adherence are not always reliable. 31 The factors associated with poor adherence to treatment in the diagnostic group under review were medication side-effects and lack of insight. Poor insight contributed to a 5.2-times increase in the risk of relapse -a finding that is consistent with other studies. 12 However, other researchers argue that the relationship between insight and adherence is not always straightforward and may be without a direct relationship; 36 e.g. it is possible that the lack of insight in this population might be related to a lower level of formal education and a lack of understanding of mental illness and its phenomena.
Patients who default on their treatment have said that treatment side-effects 14,37 together with complex treatment regimens 38 are the main reasons for their poor adherence. The majority of our patients were on typical antipsychotic medication and reported side-effects (mostly extra-pyramidal effects and impotence) as contributing to their poor adherence, which is similar to other reported findings. 39 However, this association between medication side-effects and adherence is not generally clearly established 40, 41 because many patients adhere to their medication despite treatment side-effects, 12 and a history of sideeffects is not always predictive of future non-adherence. 36 Further, recent studies report no added benefits of the atypicals in terms of efficacy, discontinuation rates, adverse effects or quality of life, compared with the typical antipsychotics.
32,33,42-45
Depressed mood
A quarter of all patients developed a depressed mood during the period studied, increasing the risk of a relapse by 5.3 times.
Other studies on depression associated with schizophrenia show a variation ranging from a high of 75% to a low of 7%. 26, 46 Depression symptoms may appear at any time during the course of schizophrenia and contribute to relapse and a decrease in quality of life. 47, 48 However, this is contradicted by Robinson et al. 49 who reported that despite a possible relationship between mood symptoms and relapse, neither the severity of baseline depressive symptoms nor the presence of mood symptoms was related to relapse and had no prognostic value. Despite these contradictory findings, early detection and management of depression symptoms may decrease the risk of psychotic relapse and it is therefore important that mental health practitioners should identify depressive moods and separate them from the deficit (negative) features of schizophrenia.
Substance abuse
Although substance abuse was very common among our study population, there was no significant association with relapses. This finding differs from previous findings of strong associations with relapses [50] [51] [52] and a greater risk of re-hospitalisation. 53 Substance abuse may exacerbate psychotic symptoms, and abused drugs may also lead to transient symptom reduction. 54 However, some studies report no association between substance abuse and relapse. 55 It must be emphasised nevertheless that although it is not clear that substance abuse in patients with schizophrenia results in relapse, it does lead to inter alia increased psychosocial problems, infections, sexually risky behaviour, and hostile and disorganised behaviour -and more so in the presence of other health-related problems, poverty, insufficient food, poor housing and widespread unemployment.
Co-morbid medical illnesses
Surprisingly, only a third of the patients with relapses had comorbid medical illnesses, despite published reports that co-morbid medical disorders exacerbate the relapse process. 56 
Limitations
Other reported factors associated with relapses (such as premorbid level of functioning, expressed emotion and duration of untreated psychosis) were not considered in this study and would be better obtained via other study designs. Moreover, the small sample size might have limited our ability to detect statistically meaningful differences.
In any retrospective study design, some data might not have been recorded in case notes, and patients might have been erroneously included or excluded. The design also raises the question of patients' ability to recall events over several weeks between clinic visits, which is compounded by the fact that patients with schizophrenia suffer from some cognitive impairment. However, the majority of our patients' records contained all the data required, and the conclusions drawn are therefore reliable. The study is generalisable, insofar as our study population experiences socio-politico-economic factors and resources that are similar to those experienced by average South African patients with schizophrenia.
Conclusions
Despite recent therapeutic progress, relapse in schizophrenia is a common and major problem among South Africans. The presence of a co-morbid depressed mood, poor adherence due to a lack of patient insight, and medication side-effects appear to be the factors most likely to increase the risk of a relapse. It is important that, in a local context, the treating psychiatrist identifies and treats mood features along with establishing ways of improving insight and adherence to treatment. If atypical antipsychotic treatments (versus typical antipsychotics) can improve adherence rates, significant reductions in relapse rates and service costs could result.
